Portopulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH) that can develop as a complication of portal hypertension. Treatment of PoPH includes PAH-specific therapies, and in certain cases, such therapies are necessary to facilitate a successful liver transplantation. A significant number of barriers may limit the adequate treatment of patients with PoPH and explain the poorer survival of these patients when compared to patients with other types of PAH. Until recently, only one randomized controlled trial has included PoPH patients, and the majority of treatment data have been derived from relatively small observational studies. In the present article, we review some of the barriers in the treatment of patients with PoPH and implications for liver transplantation. (Hepatology 2019;69:431-443). P ortopulmonary hypertension (PoPH) is defined as pulmonary arterial hypertension (PAH) associated with portal hypertension of intrahepatic or extrahepatic origin.
Treatment Barriers in Portopulmonary Hypertension
Batool AbuHalimeh, 1 P ortopulmonary hypertension (PoPH) is defined as pulmonary arterial hypertension (PAH) associated with portal hypertension of intrahepatic or extrahepatic origin. (1, 2) PAH requires a specific hemodynamic profile that includes a resting mean pulmonary arterial pressure (mPAP) ≥25 mm Hg, a pulmonary artery wedge pressure (PAWP) ≤15 mm Hg, and a pulmonary vascular resistance (PVR) >3 Wood units. (3, 4) Meanwhile, portal hypertension is defined as a portal venous gradient of ≥6 mm Hg. (5) The prevalence of PoPH is 1%-6% in patients with portal hypertension (6) (7) (8) and 5% in candidates for liver transplantation. (9) Patients with PoPH have worse survival rates than individuals with other types of PAH. (10, 11) In fact, the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) showed a 5-year survival of 40% for patients with PoPH (n = 174) compared with 64% for individuals with idiopathic or heritable PAH, even when the pulmonary hemodynamic profile appeared more favorable in PoPH subjects. (10) Interestingly, at the time of enrollment in this registry, patients with PoPH were less likely to be treated for PAH. (10) In the United Kingdom National PAH registry, treatment-naive patients with a recent diagnosis of PoPH (n = 110) had a 5-year survival of 35%, worse than patients with idiopathic PAH.
PAH-specific treatment is indicated for patients with PoPH (2, 12) ; however, the long-term impact of this approach remains largely unexplored, (13, 14) with some studies questioning its efficacy. (11, 15) Importantly, liver transplant mortality increases in patients with PoPH, particularly in subjects with mPAP ≥35 mm Hg and PVR >3 Wood units. (16, 17) In patients with this unfavorable hemodynamic profile, PAH-specific therapies are used to improve pulmonary hemodynamics and right heart function, with the expectation of decreasing the perioperative mortality of liver transplantation. (18, 19) All but one of the randomized studies that led to the Food and Drug Administration (FDA) approval of current PAH-specific medications excluded patients with PoPH. (20) Relatively small observational studies reported on the use of PAH-specific medications 432 to treat patients with PoPH. (21, 22) These data remain insufficient to adequately guide evidence-based treatment decisions (Table 1) . In addition, patients with PoPH appear to have frequent side effects with recommended doses of PAH medications, particularly prostacyclin analogues (Fig. 1) . We examined the available literature and questioned whether (1) the presence of advanced liver disease increases the incidence of side effects in patients treated with PAH-specific therapies and (2) the worse outcomes observed in patients with PoPH are in part related to barriers in receiving adequate PAH treatment.
Establishing the Diagnosis of PoPH
An accurate diagnosis of PoPH is essential because patients with advanced liver disease have other reasons for pulmonary hypertension (PH) such as volume overload and hyperdynamic state, conditions that may not necessarily impact liver transplant outcomes. (23) A right heart catheterization is required, both to confirm the diagnosis of PH (mPAP ≥25 mm Hg) and to establish the origin. In cases of volume overload and/or hyperdynamic state, the PAWP (>15 mm Hg) and/or cardiac index (≥4 L/minute/m 2 ) are elevated, while the PVR remains below 3 Wood units (or 240 dynes · s · cm -5 ). (24) Volume overload is treated with diuresis, with careful attention to renal function. A hyperdynamic state is inherent to the liver disease given splanchnic vasodilation and intrahepatic and/or mesenteric arteriovenous shunts (25) ; hence, there are no specific treatments for this condition apart from liver transplantation. (26) Importantly, other comorbidities (anemia, obesity, arteriovenous connections, beriberi, and hyperthyroidism) that increase the cardiac index need to be recognized. (27) 
Effect of PAH-Specific Therapies in PoPH
The goals of treating patients with PoPH are to alleviate symptoms, facilitate liver transplantation, and, ultimately, improve outcomes. A meta-analysis of 12 studies that included patients with PoPH showed that PAH-specific therapies improved pulmonary hemodynamics and functional capacity. (28) Observational studies suggest that PAH-specific treatment may improve outcomes when compared to historical data (12) and potentially increase the eligibility and reduce the risks associated with liver transplantation. (29, 30) However, it remains unclear whether PAH-specific treatment impacts transplant-free survival, particularly because any potential survival advantage may be curtailed by the advanced liver disease and associated comorbidities. (11, 15) Recent analyses on three PH registries suggest that PAH patients who sustain or achieve a low-risk category (31) during follow-up have better prognosis. (32) (33) (34) However, one registry (33) excluded patients with PoPH, and the other two (32, 34) included a limited number of patients with this condition (2.6% and 5.6% of the entire cohort). It remains unclear whether an aggressive PAH-specific treatment, aimed at achieving low-risk criteria, is beneficial in PoPH patients, particularly when the hemodynamic goals for liver transplant are achieved. Moreover, the parameters used to define these risk criteria, i.e., World Health Gough and White (88) 
Endothelin receptor antagonists
Hoeper et al. 
34
II-IV Mean ± SD, 696 ± 264 Bosentan 62.5 mg twice daily for 4 weeks, increased to 125 mg twice daily C-P: A, B Improvement in functional class, exercise tolerance, and cardiopulmonary hemodynamics. Three patients died of right heart failure. Elevation of liver enzymes was noted in several patients.
Cartin-Ceba et al. One patient underwent successful liver transplantation. One patient had periorbital bleeding, peripheral edema, and 8-pound weight gain. No evidence of liver toxicity.
Prostacyclin analogues
Krowka et al. Long-term phase: no improvement in cardiopulmonary hemodynamics. One patient died of worsening heart failure, and another had sudden death after successful liver transplantation.
Awdish and Cajigas Ashfaq et al. (30) 16 II-IV Mean ± SD: Moderate PoPH (n = 6), 402 ± 87 Severe PoPH (n = 10), 551 ± 92 IV epoprostenol (n = 15, 2 patients also received bosentan). One patient was treated with diltiazem.
C-P: B, C MELD: mean ± SD, Moderate 11.9 ± 4.5 Severe 15.2 ± 4.6 Improvement in cardiopulmonary hemodynamics. Eleven patients were successfully transplanted.
Sussman et al. (92) 8 N/A Mean, 410 IV epoprostenol at 2-8 ng/kg/minute MELD: mean ± SD, 17 ± 6.4 Improved cardiopulmonary hemodynamics. Six patients were listed for liver transplantation (4 were successfully transplanted).
Hoeper et al. (46) 31 II-III Mean ± SD: 812 ± 337 (iloprost) and 866 ± 422 (bosentan)
Iloprost 5 μg inh 6 times daily (n = 13) or bosentan 125 mg twice daily (n = 18) C-P: A, B MELD: mean ± SD, 12 ± 3 and 10 ± 3 Bosentan was safe. Compared with iloprost, patients treated with bosentan had better effects on exercise capacity and hemodynamics and higher survival and event-free survival.
Fix et al. (93) 19 II-IV Mean, 670 (95% CI 556-784) Epoprostenol (n = 19). In 7 patients sildenafil was added.
C-P: A, B, C MELD: median (range), 14 (7-26) Improved cardiopulmonary hemodynamics. Two patients underwent liver transplantation. Epoprostenol was discontinued in 2 and sildenafil in 4 patients given side effects.
Abbreviations: BNP, brain natriuretic peptide; CI, confidence interval; C-P, Child-Pugh score; inh, inhaled; IQR, interquartile range; IV, intravenous; N/A, not available; SD, standard deviation. Organization (WHO) functional class, 6-minute walk distance, (35) N-terminal prohormone of brain natriuretic peptide, (36) and hemodynamic determinations, (37, 38) are inherently affected in patients with liver cirrhosis and therefore may not change with PAH treatment.
PAH-Specific Therapies Used in PoPH pHoSpHoDIeSteRaSe-5 INHIBItoRS
Sildenafil was found to be effective at improving functional class, exercise tolerance, and hemodynamics in PoPH (Table 1) . Limited information exists on the use of once-a-day tadalafil in PoPH. (39) 
SolUBle gUaNylate CyClaSe StIMUlatoR
The PATENT-1 study randomized patients with PAH to the soluble guanylate cyclase stimulator riociguat or placebo and included a limited number of PoPH patients (n = 13; 11 subjects received riociguat and 2 placebo). (20) Riociguat appeared to improve functional and hemodynamic determinations in patients with PoPH; however, some patients experienced side effects (headaches [n = 3] and peripheral edema [n = 3]). In addition, one patient died of sepsis related to bronchopneumonia, an event not ascribed to the study drug. (40) 
eNDotHelIN ReCeptoR aNtagoNIStS
Hoeper et al. (41) reported improvements in symptoms, exercise capacity, and hemodynamics in PoPH patients treated with bosentan, a medication that was well tolerated. Similar results were reported by other investigators (Table 1) . Bosentan causes an elevation of liver transaminases ≥3-fold the upper limit of normal in ~11% of patients; however, ambrisentan and macitentan rarely cause hepatotoxicity. Ambrisentan has been associated with dramatic improvements in hemodynamics and WHO functional class in PoPH patients. (42) A randomized, double-blind clinical study (PORTICO, NCT02382016) testing macitentan in 
pRoStaCyClIN aNalogUeS aND pRoStaCyClIN ReCeptoR agoNISt
Intravenous epoprostenol has been used in PoPH patients as a means of improving their hemodynamic profile to facilitate liver transplant (Table 1) . Treprostinil is a chemically stable analogue of prostacyclin, and its intravenous formulation has been used in PoPH patients with success. (43) Continuous intravenous infusions of epoprostenol and treprostinil require active participation of the patient and/or caregiver. This fact is important because 30%-45% of patients with advanced liver disease develop hepatic encephalopathy, a condition associated with difficulties in performing activities of daily living, (44, 45) which can complicate treatment with parenteral medications. For instance, subjects may accidentally disconnect their intravenous access or may not be able to replace medication cassette reservoirs given agitation, confusion, and/or somnolence. Furthermore, inadequate manipulation of vascular catheters can lead to catheter malfunction, bleeding, and/or bloodstream infections.
Inhaled iloprost has been associated with longterm improvements in symptoms and exercise tolerance in PoPH. (46, 47) Limited data exist on the use of inhaled treprostinil in patients with PoPH. (48) Oral treprostinil has not been studied in patients with PoPH. Selexipag, an oral prostacyclin receptor agonist, has not been examined in patients with PoPH. Beraprost, an oral prostacyclin analogue not available in the United States, was used in a patient with PoPH who exhibited improvements in symptoms, functional capacity, and hemodynamic determinations. (49) We use inhaled treprostinil or oral treprostinil or selexipag very carefully, paying particular attention to side effects and considering longer dosing intervals, lower doses, and slower titration.
Interestingly, a retrospective study in PoPH patients compared treatment with inhaled iloprost (n = 13) versus oral bosentan (n = 18) and showed that both treatments were safe; however, patients treated with bosentan had a distinct improvement in functional capacity and pulmonary hemodynamics, with better overall and event-free survival at 1, 2, and 3 years. (46) 
Influence of Liver Disease on the Metabolism of PAH Medications
Except for epoprostenol, the liver is the predominant metabolic site for PAH-specific medications (Table 2) ; therefore, PAH medications are expected to have a longer half-life and higher serum concentration in patients with liver disease, factors associated with more frequent medication side effects. (50) In addition, the capacity of the liver to metabolize drugs depends on its blood flow and enzyme activity, both of which can be affected in patients with liver disease. (51) In support of this, Savale et al. noted that the plasma concentration of bosentan in patients with PoPH (Child-Pugh class B cirrhosis) was higher than that in individuals with idiopathic PAH, possibly due to a decrease in the liver uptake of bosentan, given lower efficiency of the organic anion transporter peptide. (52) Frey et al. demonstrated a higher riociguat exposure (after a single oral dose) in individuals with Child-Pugh class B cirrhosis than healthy controls. (53) Phosphodiestearase-5 inhibitors are metabolized by the cytochrome P450 system (CYP3A4) and rarely cause liver injury. (54) Endothelin receptor blockers are also metabolized by the cytochrome P450 system (CYP3A4, CYP2C9, and CYP2C19). A dose-dependent rise in liver function tests was observed in individuals receiving bosentan in its landmark trial (BREATHE-1), (55) possibly due to accumulation of cytotoxic bile that leads to liver cell damage. (56) A relatively small study in patients with PoPH treated with ambrisentan (n = 13) showed no changes in hepatic transaminases. (42) McGoon et al. (57) found that ambrisentan, at lower than the FDA-approved dose, was well tolerated (without significant increases in liver function tests) in patients (n = 36) who had experienced liver function test abnormalities while receiving bosentan or sitaxsentan.
Epoprostenol is metabolized by rapid hydrolysis and causes limited (<1%) hepatic side effects. Treprostinil and iloprost are metabolized by the liver (CYP2C8 and beta-oxidation, respectively). Some studies suggest that prostacyclin analogues exert a cytoprotective action on liver cells, an effect that might be beneficial in patients with PoPH. (58, 59) Peterson et al. showed that the clearance of a single dose of oral treprostinil decreased with the severity of the hepatic impairment, resulting in higher plasma levels (~8-fold higher in patients with severe hepatic impairment) and more side effects. (60) Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; C-P, Child-Pugh; GERD, gastroesophageal reflux disease; inh, inhaled; IV, intravenous; PO, orally (per os); SQ , subcutaneous; UGT, uridine 5′-diphosphate glucuronosyltransferase.
The Side Effects of PAHSpecific Medications Overlap With the Clinical Manifestations of Liver Disease
Patients with advanced liver disease have characteristic clinical manifestations, inherent to their disease and treatments, including nausea, vomiting, diarrhea, abdominal distension, anorexia, fatigue, malaise, weight loss, and fluid retention. (61, 62) Patients with liver disease who develop PoPH might present with fatigue, dyspnea, dizziness, ascites, and peripheral edema, especially as right heart failure ensues. (63) These clinical manifestations may overlap with common side effects of PAH-specific medications such as nausea, vomiting, anorexia, and edema (Table 3) , making it difficult to correctly attribute the origin of certain signs and symptoms to underlying medical conditions or side effects of PAH medications.
In order to prevent or reduce side effects, PAH medications can be started at lower doses or titrated slowly; in addition, combination therapy can be initiated sequentially instead of concurrently to be able to ascribe side effects to a particular PAH medication. However, a gentle initiation and titration of PAH-specific medications may extend the time needed to achieve the pulmonary hemodynamic goals for liver transplantation, potentially delaying listing and increasing the risk of complications due to the underlying liver disease.
Effect of PAH-Specific Medications on Portal Hypertension
There are limited data on the effect of PAHspecific medications on portal hypertension. The hepatic sinusoidal resistance is in part regulated by the nitric oxide-cyclic guanosine monophosphate system. (64) Portal pressure may increase when there is a decrease in nitric oxide release by the liver sinusoidal endothelial cells, (65, 66) an effect that could be mitigated by phosphodiesterase-5 inhibitors. (67) Phosphodiesterase-5 inhibitors decrease the hepatic sinusoidal resistance (68) but also increase the splanchnic blood flow, (69) accounting for the variable effects on the hepatic venous pressure gradient. (39, 70, 71) Riociguat reduced the portal pressure in an animal model of biliary cirrhosis, (72) but no data are available in humans.
Endothelin increases the intrahepatic vascular resistance, leading to portal hypertension. (73, 74) In rats Restrictive criteria to obtain MELD exception points based on PoPH (94) c. Not appreciating or recognizing the positive treatment effect on PVR, cardiac output, and right ventricular function when minimal changes in mPAP occur (23) d. Limited studies documenting dose reduction or discontinuation of PAH-specific therapies post-liver transplant with biliary cirrhosis, bosentan decreased the portal pressure by reducing the hepatocollateral vascular resistance. (75) In a mouse model of cirrhosis, chronic administration of endothelin receptor antagonists caused a reduction in liver fibrosis and portal pressure. (76) Prostacyclin analogues increase the hepatic blood flow. (77, 78) In an animal model of biliary cirrhosis, prostacyclin administration did not affect portal pressure. (77) In patients with PoPH (n = 8), Melgosa et al. showed that the hepatic venous pressure gradient and hepatic blood flow did not change at 30 and 60 minutes after the inhalation of iloprost. (47) 
Factors to Consider in the Selection of PAH-Specific Therapies
When prescribing PAH-specific medications to patients with PoPH, it is important to consider the presence of certain signs and symptoms as well as underlying medical conditions (e.g., renal failure). Patients with severe fluid retention may not be good candidates for endothelin receptor antagonists, and patients with pronounced nausea and dyspepsia may not tolerate prostacyclin analogues. In addition, certain interactions are important to consider: ethanol may enhance the hypotensive effects of phosphodiesterase-5 inhibitors and increase the absorption of oral treprostinil, organic nitrates may increase the vasodilatory effect of phosphodiesterase-5 inhibitors, and cyclosporine may increase the serum concentrations of bosentan and ambrisentan.
Before making treatment decisions, it is essential to assess patients' living conditions, social support, adherence to other treatments, capacity to be educated on the use of different PAH-specific medications, insurance drug coverage, copays, and eligibility for medication assistance programs.
Factors Affecting the Treatment of PoPH
Certain factors germane to patients with PoPH (Table 3 ) may affect the intensity (1) (2) (3) and hence the effectiveness of PAH-specific therapies. (79) Importantly, studies have shown that appropriate dosing as well as the use of combination therapy improve outcomes in PAH patients. (80) (81) (82) The REVEAL registry included 118 patients with PoPH, of whom 56% were treated with phosphodiesterase-5 inhibitors, 29% with intravenous or subcutaneous prostacyclin analogues, 14% with inhaled or oral prostacyclin analogues, and 7% with endothelin receptor antagonists, with 16% having received no PAH-specific therapy at the time of inclusion. The proportion of treatment-naive patients decreased at 90 (11%) and 365 (5%) days from enrollment. Interestingly, patients with PoPH were less likely to receive PAH-specific treatment both at enrollment and at 90 days compared to subjects with idiopathic or heritable PAH. (10) In our experience, side effects of PAH medications appear to be more pronounced in patients with PoPH that other types of PAH.
Swanson proposed to divide PoPH patients in two groups based on PAH severity. Patients with stable liver disease and mild to moderate PAH could be treated with oral therapies, with drug escalation based on response. Meanwhile, patients with moderate to severe PAH, particularly those with unstable liver disease, need to be treated more aggressively with parenteral prostacyclin therapy. (83) The intensity of treatment depends on the severity of PAH and the degree of hemodynamic improvement required for liver transplantation. We particularly focus on decreasing the PVR because the mPAP may remain elevated due to a high PAWP in the setting of volume overload or high cardiac output from the inherent hyperdynamic state-a key point to remember especially in liver transplant candidates.
Impact of PAH-Specific Therapies on Liver Transplantation Eligibility
There is no standardized approach for the management of PoPH, particularly in patients who are considered for liver transplantation. The general goals of treatment are similar to those of guidelines recommended for other PAH types. (31, 84) The hemodynamic treatment goal for safe liver transplantation (mPAP <35 mm Hg and PVR <5 Wood units or PVR <3 Wood units irrespective of mPAP with satisfactory right ventricular function by echocardiogram (22) , espoused by International Liver Transplantation Society guidelines, can be attained through numerous medication options. (17) This hemodynamic target for liver transplantation fluctuates among the institutions based on their multidisciplinary evaluation, comorbidities, inclusion of PVR in the hemodynamic evaluation, and prior experiences with similar patients. Although predictors of waitlist mortality exist, i.e., PVR and Model for End-stage Liver Disease (MELD) score, (94) there are no clear predictors of treatment response. Until prospective studies address this issue, it may be prudent to use intravenous prostacyclin analogues and or combination therapies in the most severe cases of PoPH, especially if liver transplantation is to be considered. (85) For example, in a liver transplant candidate with normal right ventricular function, a mPAP of 40 mm Hg, cardiac index of 4.3 L/minute, and PVR of 3.5 Wood units, treatment with an oral PAH-specific therapy might be sufficient to achieve the goal of a mPAP <35 mm Hg or PVR <3 Wood units. In contrast, in a liver transplant candidate with dilated and dysfunctional right ventricle with mean PAP of 50 mm Hg, cardiac index of 2.2 L/minute, and PVR of 9 Wood units, parenteral prostacyclin analogues, sometimes in combination with oral agents, offer the best chance to meet the hemodynamic goals and list the patient for liver transplantation. Importantly, regardless of therapies, transplant in the setting of PoPH remains higher risk and resolution of PoPH posttransplant is unpredictable. In addition, attaining an improvement and ideally a normalization of right ventricular function is of great importance, especially in transplant candidates.
Conclusions
Treatment of PoPH patients is challenging and needs to be individualized. In comparison with treatment in other types of PAH, patients with PoPH have frequent side effects that limit the use of certain medications and the dose achieved. Furthermore, in patients with PoPH it is critical to optimize the clinical condition and hemodynamic status to minimize the perioperative risk associated with liver transplantation.
